@AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue Reading@AllogeneTx: Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue Reading@AllogeneTx: This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Continue ReadingAllogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology